Johnson & Johnson to pay $2.2B over allegations
November 5 , 2013
Johnson & Johnson and its subsidiaries are soon to pay over $2.2B in order to resolve civil and criminal allegations.
The company allegedly paid kickbacks to pharmacies and physicians to promote two antipsychotic drugs namely, Risperdal and Invega as well as Natrecor, which is a drug used to treat heart failure.
Civil settlements in the figure amount to $1.7B and criminal fines as well as forfeited profits amount to $485M.
This is the largest settlement involving a drugmaker in the US; a drugmaker in Britain paid $3B in fines to settle violations last year.